CRAIG EAGLE - 01 Jan 2026 Form 4 Insider Report for Guardant Health, Inc. (GH)

Role
Chief Medical Officer
Signature
/s/ John G. Saia, as attorney-in-fact for Craig Eagle
Issuer symbol
GH
Transactions as of
01 Jan 2026
Net transactions value
-$1,176,857
Form type
4
Filing time
05 Jan 2026, 17:58:43 UTC
Previous filing
17 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
EAGLE CRAIG Chief Medical Officer 3100 HANOVER STREET, PALO ALTO /s/ John G. Saia, as attorney-in-fact for Craig Eagle 05 Jan 2026 0001562135

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GH Common Stock Options Exercise $0 +1,714 +3.8% $0.000000 46,721 01 Jan 2026 Direct
transaction GH Common Stock Options Exercise $0 +13,714 +29% $0.000000 60,435 01 Jan 2026 Direct
transaction GH Common Stock Options Exercise $0 +1,667 +2.8% $0.000000 62,102 01 Jan 2026 Direct
transaction GH Common Stock Options Exercise $0 +5,688 +9.2% $0.000000 67,790 01 Jan 2026 Direct
transaction GH Common Stock Options Exercise $0 +2,659 +3.9% $0.000000 70,449 01 Jan 2026 Direct
transaction GH Common Stock Tax liability $1,176,857 -11,522 -16% $102.14 58,927 01 Jan 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GH Restricted Stock Units Options Exercise $0 -1,714 -25% $0.000000 5,143 01 Jan 2026 Common Stock 1,714 $0.000000 Direct F2, F3
transaction GH Performance-Based Restricted Stock Units Options Exercise $0 -13,714 -100% $0.000000 0 01 Jan 2026 Common Stock 13,714 $0.000000 Direct F3, F4
transaction GH Restricted Stock Units Options Exercise $0 -1,667 -25% $0.000000 5,002 01 Jan 2026 Common Stock 1,667 $0.000000 Direct F3, F5
transaction GH Performance-Based Restricted Stock Units Options Exercise $0 -5,688 -50% $0.000000 5,688 01 Jan 2026 Common Stock 5,688 $0.000000 Direct F3, F6
transaction GH Restricted Stock Units Options Exercise $0 -2,659 -12% $0.000000 18,615 01 Jan 2026 Common Stock 2,659 $0.000000 Direct F3, F7
holding GH Performance-Based Restricted Stock Units 13,714 01 Jan 2026 Common Stock 13,714 $0.000000 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
F2 This represents a restricted stock unit award granted on November 7, 2022 that vests over a four-year period. 25% of the shares subject to such award vested on October 1, 2023 and the remaining 75% of the shares vests in equal quarterly installments over the remaining three-year period thereafter.
F3 Not applicable for Restricted Stock Units.
F4 This represents a performance-based restricted stock unit award granted on June 7, 2023, with a performance metric and 2-year vest period that was achieved. The shares vested on January 1, 2026.
F5 This represents a restricted stock unit award granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
F6 This represents a performance-based restricted stock unit award granted on February 26, 2024, that a performance metric was achieved and that 33% of the shares subject to such award vested on March 1, 2025. 33% of the shares subject to the award vested on January 1, 2026, and the remaining 34% of the shares subject to the award will vest on January 1, 2027.
F7 This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.